Psychiatric Comorbidity of Cannabis Use Disorder David Gorelick In book : "Cannabis Use Disorders", January 2019 DOI : 10.1007/978-3-319-90365-1_13 Abstract : Objective : This chapter reviews the epidemiology and treatment of cannabis use disorder (CUD) with psychiatric comorbidity. Methods : We summarize the findings of English-language epidemiological studies reporting current (past-year) comorbidity and of controlled clinical trials of treatment in which the majority of participants had diagnosed CUD and a specific comorbid disorder. Results : There is substantial CUD comorbidity among community-dwelling adults with major psychiatric disorders: 4–6% for depression, 14% for bipolar disorder, 5% for anxiety disorder, and 16% for schizophrenia. Conversely, there is substantial psychiatric [...]
Lire la suiteEndocannabinoid System Aleksandra Tarasiuka, Maciej Salagaa, and Jakub Fichna, Medical University of Lodz, Lodz, Poland Encyclopedia of Gastroenterology, 2nd Edition © 2019 Elsevier Inc. All rights reserved. https://doi.org/10.1016/B978-0-12-801238-3.65635-0 Introduction 1 Cannabinoids and Their Role in the Physiological and Pathophysiological Processes in the GI Tract 3 Physiological Conditions 3 Gut motility 3 Gastric secretion and emptying 3 Pathophysiological Conditions 4 IBS 4 IBD 5 Colon cancer 5 Peptic ulcer disease 5 Endocannabinoid System and Its Interplay With Other Systems 5 Cholecystokinin 5 Endovanilloids 6 Opioids 6 Endocannabinoid System and Gut Microbiota 6 Conclusion 7 Acknowledgments 7 References Introduction Endocannabinoid system (ECS) is one of the crucial physiological systems that may be targeted to improve human health. Endocannabinoids and their receptors are localized in various organs [...]
Lire la suiteBIBLIOGRAPHIE : Cannabinoïdes, Dépression et Troubles de l’Humeur Docteur Christian SUEUR, GRECC, novembre 2019.
Lire la suiteBipolar disorder and the endocannabinoid system Shokouh Arjmand, Mina Behzadi, Kristi A. Kohlmeier, Shahrzad Mazhari, Abdolreza Sabahi and Mohammad Shabani Acta Neuropsychiatrica, 2019, 1-9. https://doi.org/10.1017/neu.2019.21 Abstract Objective : Bipolar disorder (BD) is a debilitating, lifelong neuropsychiatric illness characterised by unsteady mood states which vacillate from (hypo)mania to depression. Despite the availability of pharmaceutical agents which can be effective in ameliorating the acute affective symptoms and prevent episodic relapse, BD is inadequately treated in a subset of patients. The endocannabinoid system (ECS) is known to exert neuromodulatory effects on other neurotransmitter systems critical in governing emotions. Several studies ranging from clinical to molecular, as well as [...]
Lire la suiteRole of the Endocannabinoid System in the Pathophysiology of Schizophrenia: Implications for Pharmacological Intervention F.M. Leweke, J.K. Mueller, B.Lange, S. Fritze, C.E. Topor, D. Koethe, C. Rohleder CNS Drugs, 2018 Jul;32(7):605-619. doi: 10.1007/s40263-018-0539-z. Abstract The term schizophrenia describes a group of multifaceted psychiatric conditions causing significant impairment of the quality of life of affected patients. Although multiple pharmacological treatment options exist, e.g. first- or second-generation antipsychotics, these therapeutics often cause disturbing side effects, such as extrapyramidal symptoms, prolactin increase, sexual dysfunction and/or metabolic syndrome. Furthermore, cognitive impairments and negative symptoms, two factors significantly influencing the course and outcome, are not sufficiently addressed by the available [...]
Lire la suiteChildhood trauma and being at-risk for psychosis are associated with higher peripheral endocannabinoids E. Appiah-Kusi, R. Wilson, M.Colizzi, E. Foglia, Sagnik Bhattacharyya, et al. Psychological Medicine, 2019. DOI: https://doi.org/10.1017/S0033291719001946 Published online by Cambridge University Press: 19 August 2019 Abstract BackgroundEvidence has been accumulating regarding alterations in components of the endocannabinoid system in patients with psychosis. Of all the putative risk factors associated with psychosis, being at clinical high-risk for psychosis (CHR) has the strongest association with the onset of psychosis, and exposure to childhood trauma has been linked to an increased risk of development of psychotic disorder. We aimed to investigate whether being at-risk for [...]
Lire la suiteUne université de Houston teste la psilocybine pour la dépression résistante aux traitements - www.NEWSWEED.fr 22 octobre 2019 Aurélien BERNARD Dans la foulée de sa décriminalisation dans quelques villes des États-Unis (Oakland et Denver notamment), la psilocybine intéresse actuellement la communauté scientifique à la recherche de preuves d’efficacité thérapeutique. Des chercheurs du Science Health Center de l’Université du Texas à Houston (UTHealth) ont annoncé qu’ils étudiaient la psilocybine pour la dépression réfractaire aux traitements. PUBLICITE L’étude est inspirée par des recherches scientifiques antérieures qui suggèrent que la psilocybine agit pour créer de nouveaux circuits mentaux. Une étude de 2012 a conclu que la substance pouvait permettre [...]
Lire la suiteHallucinogens and Their Therapeutic Use : A Literature Review Matthew J. BEGOLA, Jason E. SCHILLERSTROM Journal of Psychiatric Practice, 2019, 25, (5), 334–346 Doi : 10.1097/PRA.0000000000000409 The exploration of possible therapeutic benefitsof hallucinogenic substances has undergone a revitalization in the past decade. This literature review investigated the published literature regarding the psychotherapeutic uses of hallucinogens in psychiatric disorders. The results showed that a variety of substances have been evaluated in the treatment of psychiatric disorders, including ayahuasca, ibogaine, ketamine, lysergic acid diethylamide, 3,4-methylenedioxymethamphetamine, and psilocybin. The conditions treated ranged from depression to autism, with the largest volume of research dedicated to substance use disorders. [...]
Lire la suiteIACM-Bulletin du 22 Octobre 2019 Dixième conférence de l'IACM sur les cannabinoïdes en médecine à Berlin Science/Homme: Selon une vaste enquête, une grande proportion de patients souffrant de douleur sont en mesure de réduire ou d'arrêter l'utilisation d'opioïdes Science/Homme: Selon une étude ouverte, le CBD pourrait avoir un effet positif pour la survie pour les patients atteints d’un glioblastome Science/Animal: Comment le CBD atténue les effets psychologiques du THC Science/Homme: Amélioration clinique de la maladie inflammatoire de l'intestin lors d’une étude d'observationnelle Science/Homme: Lors d’une petite étude une prise orale de cannabis a permis [...]
Lire la suiteBibliographie "Salvia divinorum" Pharmacologie, Ethnopharmacologie, Neurophysiologie, Usages Thérapeutiques..., GRECC, Dr Christian Sueur, octobre 2019. Salvia divinorum : généralités, usages, sociologie.....................................................................................1 Salvia divinorum, Salvinorin A : Neurophysiologie..................................................................................4 Salvinorin A : Pharmacologie.....................................................................................................................7 Salvia divinorum et chamanisme..............................................................................................................11 Salvia divinorum et psychiatrie................................................................................................................12 Salvia divinorum et thérapeutique...........................................................................................................13
Lire la suite